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drug treatment, occupational advancement, current work status, and direct cost was 
detected in univariate analyses. CONCLUSIONS: To our best knowledge this is the 
ﬁrst observational study on the burden of GTS in Germany. With annual total costs 
of about a12,500, GTS places a notable ﬁnancial burden on society. HrQoL is 
 considerably reduced in patients with GTS. While tic treatment is important, co-
 morbidities such as depression should be regarded more seriously.
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OBJECTIVES: To assess change in health-related quality of life (HRQoL) over time 
in MS patients treated with natalizumab in a “usual care setting” in the United States 
(US). METHODS: MS patients starting natalizumab were invited to participate in a 
1-year longitudinal health outcomes study assessing their experiences with natali-
zumab. MS patients complete self-reported assessments prior to natalizumab initiation 
and after the 3rd, 6th and 12th natalizumab infusions. The current analysis reports the 
change in general HRQoL assessments using the SF-12v2 from baseline through the 
6th natalizumab infusion. Physical and Mental Component Summary (PCS and MCS, 
respectively) scores were computed at each assessment. PCS and MCS scores range 
from 0 to 100, with higher scores indicating better HRQoL. The a-priori study 
hypothesis was that patient-reported HRQoL improves over time with longer duration 
of natalizumab treatment. Statistical regression models were used to evaluate changes 
in HRQoL over time after controlling for the number of natalizumab infusions, age, 
years since MS diagnosis, baseline disease disability and functional status, comorbidity 
burden, and number of drugs used prior to natalizumab. RESULTS: Data for 296 
patients were analyzed. The mean age was 47 / 11 years and the majority of patients 
were female (78%). The mean number of years since MS diagnosis was 11 / 9 years. 
After controlling for covariates, a statistically signiﬁcant increase (improvement) in 
PCS scores (BL 34 / 11, 3rd 36 / 12 and 6th 36 / 11; p  0.0001) and MCS 
scores (BL 43 / 12, 3rd 47 / 11 and 6th 48 / 11; p  0.0001) was observed from 
baseline through the 6th infusion. CONCLUSIONS: Patients reported signiﬁcant 
improvements in both physical and mental aspects of HRQoL over 6 months of treat-
ment, suggesting an improved effect of natalizumab over time. These results document 
the improvement in HRQoL of MS patients receiving natalizumab in the usual care 
setting and are consistent with clinical study ﬁndings.
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OBJECTIVES: Reports from clinical trials suggest that physical activity (PA) can be 
beneﬁcial for multiple sclerosis (MS) patients. However, participation in PA was found 
to be low in MS patients with substantial physical disability. We assessed levels of PA 
and their interaction with depression and health related quality of life (HRQoL) in 
early-stage MS patients. METHODS: The BEGIN study (Betaferon® treatment and 
Exercise data Gathering IN early MS) is an international prospective observational 
study of early-stage MS patients, including clinically isolated syndrome suggestive of 
MS, treated with Betaferon®. PA levels were assessed by the International Physical 
Activity Questionnaire (IPAQ) and a pedometer, and depression using the Center for 
Epidemiological Studies Depression Scale (CES-D), and HRQoL with the EuroQoL 5 
dimension (EQ-5D) utility scale and Visual Analogue Scale (VAS) score. RESULTS: 
PA data were collected from 609 patients (68.0% women) in 16 countries in Europe, 
Asia, Australia and Latin America. Mean age was 36.3 years (SD  9.9). The median 
MET-minutes/week derived from IPAQ at baseline was 3349 (SD  3616), with 
25.2%, 32.5% and 42.6% of patients categorized as low, moderate and high PA level, 
respectively. The median steps per day were 6,728 (IQR  4,942). A negative Spear-
man’s rank correlation was found between the steps per day and depressive symptoms 
(p  0.01).Mean depression scores decreased monotonically in higher IPAQ categories. 
EQ-5D utility and VAS scores were on average 0.7 (SD  0.2) and 71.7 (SD  19.5), 
respectively. The steps per day showed to be positively correlated with both VAS 
(p  0.01) and utility (p  0.01) outcomes. CONCLUSIONS: PA in early-stage MS 
patients was found to be positively associated with HRQoL. Adding the results of the 
longitudinal data after two years of follow-up may lead to further insights regarding 
the role of PA in early-stage MS patients and its relation to HRQoL.
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OBJECTIVES: To assess patient-reported treatment satisfaction with natalizumab in 
MS patients in the United States (US). METHODS: MS patients initiating natalizumab 
were invited to participate in a longitudinal study. Patients complete self-reported 
assessments prior to natalizumab initiation and then after the 3rd, 6th and 12th natali-
zumab infusions. As part of the baseline (BL) assessment, patients reported their sat-
isfaction with MS drugs used prior to natalizumab initiation. For the follow-up 
assessments, patients reported their satisfaction with natalizumab treatment. Patient 
self-reported measures included satisfaction with treatment effectiveness, convenience 
of use, and global treatment satisfaction scales from the Treatment Satisfaction Ques-
tionnaire. Each scale consists of 3 items, with responses measured on a 7-point Likert 
Scale ranging from 1 (low) to 7 (high). Individual item responses are added and scores 
are transformed to a 0 to 100 scale with higher scores indicating higher satisfaction. 
This analysis evaluates the change in satisfaction from baseline through the 6th natali-
zumab infusion after controlling for number of natalizumab infusions, age, years since 
MS diagnosis, baseline disease disability and functional status, comorbidity burden, 
and number of MS drugs used prior to natalizumab. RESULTS: Data from 296 
patients indicated that 78% are female, the mean age is 47 o 11 years and the mean 
time since MS diagnosis is 11 o 9 years. Almost all (97%) patients used at least one 
other MS drug before natalizumab. After controlling for covariates, signiﬁcant 
increases in effectiveness (BL 44.22 o 8.62, 3rd 61.91 o 6.87 and 6th 69.48 o 4.96, p 
 0.0001), convenience (BL 60.80 o 6.27, 3rd 79.18 o 3.25 and 6th 79.69 o 0.42, p  
0.0001), and global satisfaction (BL 62.46 o 3.92, 3rd 75.36 o 3.92 and 6th 76.51 o 
3.92, p  0.0001) were observed. CONCLUSIONS: Patients’ satisfaction with natali-
zumab increased with increasing treatment duration. Patients reported higher levels 
of satisfaction with treatment effectiveness, convenience of use, and global satisfaction 
while receiving natalizumab compared to their satisfaction levels with MS drugs 
received before initiating natalizumab.
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OBJECTIVES: Estimating the minimal important difference (MID) of patient reported 
outcome (PRO) measures is important to guide interpretations of scores and for 
assessing treatment efﬁcacy in clinical trials and studies. The current study was 
designed to estimate the MID of newly developed PROs for Multiple Sclerosis (MS); 
The Patient Reported Indices for Multiple Sclerosis (PRIMUS; which includes Activity 
and Quality of Life (QoL) scales) and Unidimensional Fatigue Impact Scale (U-FIS). 
The measures have been shown previously to be unidimensional, valid and reliable. 
METHODS: Data were taken from the TRANSFORMS study, a multi-country phase 
III study evaluating the safety and efﬁcacy of oral ﬁngolimod compared to IFNB-1a 
i.m. in relapsing-remitting MS patients. PRO assessments were completed at baseline, 
6 and 12 months. Measures included the PRIMUS-Activities (scored 0–30), PRIMUS-
QoL (scored 0–22), U-FIS (scored 0–66) and EQ-5D. For PRIMUS and U-FIS scales, 
a high score indicates more severe impact. Both anchor (published EQ-5D MID values) 
and distribution (0.2 and 0.5 effect sizes, standard error of measurement) based 
approaches were employed. Anchor-based MID values were assessed both for indi-
viduals who improved or deteriorated according to EQ-5D MID values. Triangulation 
of results provided the ﬁnal PRIMUS and U-FIS MID estimates. RESULTS: Trial 
sample: n  1292, 67.3% female, mean age 36.2 (SD  8.5), mean MS duration 7.4 
years (SD  6.2). Anchor and distribution based MID’s ranged from 0.9–2.9 (PRIMUS 
QoL), 0.7–2.3 (PRIMUS Activities) and 2.4–7.3 (U-FIS). Triangulation resulted in the 
following MID values; PRIMUS Activities 1.5 for individuals improving or deteriorat-
ing; PRIMUS QoL 1.5 for individuals improving or deteriorating and U-FIS 4.5 for 
those improving and 5.0 for those deteriorating. CONCLUSIONS: The analyses 
provide preliminary information on the interpretation of scores on the scales. The 
MID values will aid the assessment of treatment efﬁcacy in clinical trials and 
studies.
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OBJECTIVES: To measure the association of health-related quality of life (HRQoL) 
and pre-baseline relapse among multiple sclerosis (MS) patients in a real-world obser-
vational study. METHODS: The Real-World Betaseron Outcomes Study (ROBUST) 
is a 12-month, US prospective, observational, open-label, single-arm, multi-center 
outcomes study of interferon beta-1b given every other day for MS. Patient outcomes, 
including relapse history, were reported independently by both patients and physicians 
via a web-based data capture tool. A total of 226 patients were registered across 52 
sites, and 193 completed the baseline survey. Analysis of variance methods were used 
to measure the association of SF-12 Health Survey (SF-12) scores and pre-baseline 
relapse descriptors (relapse status, frequency, severity of typical and worst relapse). 
SF-12 results were summarized by Physical Component Score (PCS-12) and Mental 
Component Score (MCS-12). RESULTS: Both physical and mental scores were lower 
among patients reporting to be in relapse at baseline (N  78) than among those 
reporting to be relapse-free at baseline (N  115); however, the difference was statisti-
cally signiﬁcant only on the MCS-12 (43.9 vs. 40.5; p  0.045). Reduction of both 
PCS-12 and MCS-12 were strongly associated with increasing frequency of patient 
